Pathos AI completed a $237 million Series E funding round, with a post-investment valuation of approximately $3 billion

AI pharmaceutical company Pathos AI has completed a $237 million Series E financing round, with a post-money valuation of approximately $3 billion. This round was led by Bristol Myers Squibb, with participation from existing investors.

Pathos AI plans to use the new funds to expand its Foundry platform, which assists drug development through thousands of AI agents, while advancing its four cancer treatment drugs that are in clinical stages.